Skip to main content

The independent medical news service

Lung cancer

22-09-2020 | Oncology | News | Article

NSCLC CNS recurrence significantly reduced with adjuvant osimertinib

Adjuvant treatment with osimertinib substantially reduces the risk for central nervous system recurrence among patients with resected stage IB–IIIA EGFR-mutated non-small-cell lung cancer, shows an analysis of phase 3 study data.

21-09-2020 | Oncology | News | Article

Postoperative RT ‘not recommended’ for resected advanced NSCLC

Patients with completely resected stage IIIA N2 non-small-cell lung cancer do not benefit from postoperative radiotherapy, show the results of the phase 3 Lung ART trial presented at the ESMO Virtual Congress 2020.

20-09-2020 | Oncology | News | Article

Consolidation nivolumab–ipilimumab fails to boost limited-stage SCLC survival after CRT

ETOP/IFCT 4-12 STIMULI findings do not support the use of consolidation nivolumab plus ipilimumab for limited-stage small-cell lung cancer patients who have completed chemoradiotherapy and prophylactic cranial irradiation.

11-09-2020 | Oncology | News | Article

FDA approves liquid biopsy test for somatic, germline mutations

Click through to read more

07-09-2020 | Oncology | News | Article

AURA3 shows no OS benefit of osimertinib vs chemotherapy

The phase 3 AURA3 trial has failed to demonstrate a significant overall survival gain with second-line osimertinib versus platinum–pemetrexed in patients with advanced non-small-cell lung cancer carrying the EGFR T790M resistance mutation.

25-08-2020 | Oncology | News | Article

Cancer diagnoses in USA fall during COVID-19 pandemic

US researchers report “a significant decline” in the numbers of new diagnoses of six tumor types following the SARS-CoV-2 outbreak.

19-08-2020 | Oncology | News | Article

FDA approves liquid biopsy NGS technology

Read more on this announcement here

18-08-2020 | Oncology | News | Article

Consolidation pembrolizumab promising in locally advanced NSCLC

Patients undergoing chemoradiotherapy for unresectable stage III non-small-cell lung cancer could benefit from consolidation treatment with the PD-1 inhibitor pembrolizumab, suggest phase 2 study results.

12-08-2020 | Oncology | News | Article

Ensartinib ‘a new first-line option’ for ALK-positive NSCLC

The eXalt3 study has shown significantly better progression-free survival with ensartinib versus crizotinib in ALK inhibitor-naïve patients with ALK alteration-positive, advanced non-small-cell lung cancer.

11-08-2020 | Oncology | News | Article

First-line sintilimab–chemotherapy improves nonsquamous NSCLC outcomes

Treatment-naïve patients with advanced nonsquamous non-small-cell lung cancer derive a significant progression-free survival survival with the addition of the PD-1 inhibitor sintilimab to chemotherapy, indicates the ORIENT-11 trial.

03-08-2020 | Oncology | News | Article

EMA recommends new indication for durvalumab

Click through to find out more

31-07-2020 | Oncology | News | Article

Cancer diagnostic delays due to COVID-19 may lead to high excess mortality

Two modelling studies published in The Lancet Oncology show the impact cancer diagnostic delays due to COVID-19 could have in England, with some scenarios suggesting over a 1000 people could die unnecessarily.

23-07-2020 | Oncology | News | Article

Lung cancer COVID-19 guidance available

Two sets of guidance on the care of lung cancer patients during the COVID-19 pandemic have been issued.

17-07-2020 | Oncology | News | Article

Surgical delays due to COVID-19 significantly impact cancer survival

UK researchers have called for urgent action to be taken to avoid unnecessary cancer deaths as a result of delayed surgery due to the COVID-19 pandemic.

16-07-2020 | Oncology | News | Article

Atypical skin signs apparent in lung cancer patients with COVID-19

Two case studies reported in the Journal of Thoracic Oncology show that lung cancer patients receiving treatment with PD-1 inhibitors can present with atypical and severe skin manifestations when infected with SARS-CoV-2.

08-07-2020 | Oncology | News | Article

Pyrotinib activity shown in HER2-mutant NSCLC

The oral tyrosine kinase inhibitor pyrotinib is well tolerated and shows promising antitumor activity in people with HER2-mutated non-small-cell lung cancer, phase 2 study data show.

03-07-2020 | Oncology | News | Article

Potential for anticancer, COVID-19 drug interactions highlighted

A French team has drawn attention to the potential for drug–drug interactions between anticancer medications and agents being used or tested for the treatment of COVID-19.

02-07-2020 | Oncology | News | Article

Support for ‘plasma-first’ approach in molecular testing for NSCLC

Comprehensive circulating tumor DNA analysis can identify therapeutically targetable driver and resistance mutations in patients with advanced non-small-cell lung cancer, research indicates.

29-06-2020 | Oncology | News | Article

Entrectinib receives positive decision from EMA

More details about the announcement are a click away

26-06-2020 | Oncology | News | Article

First-line stereotactic radiosurgery an option for brain metastases in SCLC

Patients with small-cell lung cancer and brain metastases may benefit from first-line treatment with stereotactic radiosurgery, suggest findings from the FIRE-SCLC study.

Image Credits